ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
One-Third of Hep C Rx Receive Absolute Denial From Insurers
July 26, 2018Insurers are increasingly denying prescriptions of direct-acting antiviral (DAA) drugs for hepatitis C virus treatment, according to a study published online June 7 in Open Forum Infectious Diseases. -
Which are to Dominate the Chinese HCV Drug Market: A Review of DAAs in China
October 13, 2017So far, there are four HCV DAAs marketed in Mainland China, including the above two, BMS’ Asunaprevir soft capsule and Daclatasvir Dihydrochloride Tables combined therapy, and J & J’s Simeprevir.
Pharma Sources Insight January 2025
